Skip to main content
Clinical Trials/CTRI/2025/09/095256
CTRI/2025/09/095256
Not yet recruiting
Phase 1/2

EVALUATING THE EFFICACY OF YOGA AS AN ADJUNCT TO CONVENTIONAL TREATMENT ON SYMPTOMATIC RELIEF AND MENTAL WELL-BEING IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE

Ankit Semwal1 site in 1 country120 target enrollmentStarted: October 10, 2025Last updated:

Overview

Phase
Phase 1/2
Status
Not yet recruiting
Sponsor
Ankit Semwal
Enrollment
120
Locations
1
Primary Endpoint
Gerd Symptoms using GERDQ questionnaire

Overview

Brief Summary

Title of the Study: Evaluating the Efficacy of Yoga as an Adjunct to Conventional Treatment on Symptomatic Relief and Mental Well-Being in Patients with Gastroesophageal Reflux Disease (GERD)

Type of Study: Randomized Controlled Trial (Parallel Group Design)

Study Design and Randomization: This is a 12-week, randomized, parallel controlled study with two groups. A total of 120 participants will be enrolled, with 60 patients in each group. Randomization will be carried out using a computer-generated block randomization list. Allocation concealment will be maintained through the snoSEAL (sealed envelope) method.

Study Groups:

Group A (Intervention Group): Yoga-based intervention (specific yoga protocol) + Conventional medical treatment for GERD.

Group B (Control Group): Conventional medical treatment alone.

Sample Size: 120 participants (60 in each group).

Study Setting: The study will be conducted in the Department of Gastroenterology, Himalayan Institute of Medical Sciences (HIMS), Swami Rama Himalayan University, Dehradun, Uttarakhand, India.

Follow-up and Assessments:

Baseline and post-intervention assessments (after 12 weeks) will be done using standardized tools such as GERD-Q, GERD-HRQL, and Perceived Stress Scale (PSS).

Intervention group will follow a structured yoga protocol (35 minutes/day, 6 days/week, for 12 weeks) including diaphragmatic breathing, Nadi Shodhan, Bhramari, systematic relaxation, and meditation.

Primary Outcome Measures:

Reduction in GERD symptoms (measured by GERD-Q)

Secondary Outcome Measures:

  1. Reduction in stress levels (PSS).

  2. Improvement in quality of life (GERD-HRQL)

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
Outcome Assessor Blinded

Eligibility Criteria

Ages
18.00 Year(s) to 70.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • 1.Individuals diagnosed with erosive GERD 2.Subjects between the age group of 18 between 70
  • Both literate and illiterate
  • participants who consume alcohol occasionally.

Exclusion Criteria

  • Patients diagnosed with non-erosive reflux disease
  • Subjects who have recently undergone any thoracic and abdominal surgery
  • Patients diagnosed with Barretts esophagus
  • Patient with a diagnosis of liver cirrhosis
  • Individuals with current or past or current diagnoses of any form of malignancy
  • An individual consuming alcohol cigarettes and other drugs
  • An individual having medication that triggers GRED like calcium channel blocker beta blockers etc
  • Patients with large hiatal hernia Grade 3 and Grade 4.

Outcomes

Primary Outcomes

Gerd Symptoms using GERDQ questionnaire

Time Frame: Baseline and final assessment after 12 weeks

Secondary Outcomes

  • 1 Stress by PSS-10(2 Quality of life by GERD-HRQL)

Investigators

Sponsor
Ankit Semwal
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

Ankit Semwal

School of Yoga Science, Swami Rama Himalayan University, Jolly grant, Dehradun, India

Study Sites (1)

Loading locations...

Similar Trials